Bioshares Biotech Products Fd

Madrigal Pharmaceuticals insiders sold $1,380,816 worth of shares

Madrigal Pharmaceuticals CEO Plans to Sell 2,400 Shares of Restricted Stock

Galmed Pharmaceuticals Grants New Use Patent for ARAMCHOL in Combination with Madrigal Pharmaceuticals' REZDIFFRA

Panagora Increases Stake in Travere

Legal & General Group Increased Stake in BridgeBio Pharma

Ionis Pharmaceuticals Director Sold Company Common Stock

Madrigal Pharmaceuticals CFO Reports on Stock Disposal

Insmed Inc. CMO Reports Disposition of Common Stock

Ionis Pharmaceuticals Receives FDA Breakthrough Therapy Designation

F m Investments LLC Reduces Holdings in Insmed, Inc.

American Century Increases Holdings in Madrigal Pharmaceuticals

Ionis Pharmaceuticals Director Disposes of Company Common Stock

Ionis Pharmaceuticals EVP and CHRO Shannon L. Devers Sells Common Stock

Elizabeth M. Anderson Reports Sale of Insmed Inc. Common Stock

Neil Kumar reports disposal of BridgeBio Pharma common stock

Leerink Partners Raises Insmed's EPS Forecast

New Jersey Police and Fireman Pension System Increased Holdings in BridgeBio Pharma

Roivant Sciences Ltd. Director Sells Common Stock

QVT Financial LP sells common stock of Roivant Sciences Ltd.

Madrigal Pharmaceuticals Inc. CCO Disposes of Common Stock

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Hoyne Bancorp

Tradr 2X Long ASTS Daily ETF

MDGL

Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing

marketscreener

Madrigal Pharma

Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing

INSM

Lewis William H, Chairman of Insmed Inc, filed a Form 144 with the SEC to sell 10,699 shares on December 4, 2025, through Merrill Lynch & Co Inc. The sale is executed under a prearranged trading plan (10b5-1).

Reuters

Insmed

Chmn Lewis Files To Sell 10,699 Of Insmed Inc [INSM]

CEO Sibold William John of Madrigal Pharmaceuticals Inc filed a Form 144 with the SEC to sell 2,400 restricted shares on December 4, 2025. The sale will be managed by Morgan Stanley Smith Barney LLC. Form 144 is required for selling restricted stock, allowing the owner to sell within 90 days of filing. The Washington Service offers insider trading analysis and data services.

CEO Sibold Files To Sell 2,400 Of Madrigal Pharmaceuticals Inc [MDGL]

GLMD

Galmed Pharmaceuticals Ltd. announced the grant of new use patents for combining its drug Aramchol with Madrigal Pharmaceuticals’ Rezdiffra for MASH treatment. The patent, granted in South Korea, extends Aramchol’s U.S. patent protection until July 2042, strengthening its position in combination therapies for MASH.

Galmed Pharma

Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment

Insmed Inc. announced inducement awards to 92 new employees under its 2025 Inducement Plan. The awards include 44,273 restricted stock units and options to purchase 2,490 shares at $207.77 per share. The stock units vest over four years, contingent on continued employment. This announcement was made via PR Newswire on December 4, 2025.

Insmed Grants Inducement Awards to 92 New Employees Under 2025 Plan

TVTX

Panagora Asset Management Inc. increased its stake in Travere Therapeutics by 28.6% in Q2, acquiring 96,062 shares. Analysts have set new price targets for Travere, with Jefferies at $35, Wedbush at $32, and Piper Sandler at $35. Insider trading includes CEO Eric M. Dube selling 92,872 shares. Travere's stock opened at $33.99, with a market cap of $3.04 billion.

Market Beat

Travere Therapeutics

Panagora Asset Management Inc. Buys 96,062 Shares of Travere Therapeutics, Inc. $TVTX

BBIO

Legal & General Group Plc increased its holdings in BridgeBio Pharma by 17.5% in Q2, owning 159,573 shares worth $6.89 million. Analysts have raised price targets for BridgeBio Pharma, with Wells Fargo, Goldman Sachs, JPMorgan, Cowen, and Cantor Fitzgerald giving positive ratings. The stock opened at $74.15, with a market cap of $14.29 billion. Insider trading includes sales by Directors Hannah Valantine and Andrew Lo.

Bridgebio Pharma

Legal & General Group Plc Purchases 23,716 Shares of BridgeBio Pharma, Inc. $BBIO

IONS

Wender Joseph H, Director of Ionis Pharmaceuticals Inc, sold 28,000 shares worth $2.3 million on December 1, 2025, as disclosed in a Form 4 filing with the SEC. The sale was executed under a prearranged trading plan (10b5-1). After the sale, Wender holds 52,035 shares.

Ionis Pharma

Dir Wender Sells 28,000 ($2.3M) Of Ionis Pharmaceuticals Inc [IONS]

Joseph H. Wender, Director at Ionis Pharmaceuticals Inc., reported selling common shares of the company. The filing is available via EDGAR, the SEC's system. This news is AI-generated by Public Technologies and is not financial advice.

Ionis Pharmaceuticals Director Joseph H. Wender Reports Sale of Common Shares

Mardi Dier, CFO of Madrigal Pharmaceuticals Inc., reported the disposal of common shares of the company. The full filing is available via EDGAR, the SEC's system. This news brief was created by Public Technologies using AI and is for informational purposes only.

Madrigal Pharmaceuticals CFO Mardi Dier Reports Disposal of Common Shares

Christopher R. Cline, CFO of Travere Therapeutics Inc., reported a disposal of common shares. The full filing is available via EDGAR, the U.S. SEC's system. This news brief was created by Public Technologies using AI and is for informational purposes only.

Travere Therapeutics CFO Christopher R. Cline Reports Disposal of Common Shares

Insmed Insider Sold Shares Worth $1,841,101, According to a Recent SEC Filing

Insmed Insider Sold Shares Worth $1,841,101, According to a Recent SEC Filing

Martina Flammer, Chief Medical Officer of Insmed Inc., has reported the disposal of common shares of the company. The details were published via EDGAR by Insmed Inc. on December 3, 2025. This information is provided by Public Technologies and is not intended as financial advice.

Insmed Chief Medical Officer Martina Flammer Reports Disposal of Common Shares

Loomis Sayles & Co. L P reduced its holdings in Travere Therapeutics by 41.3% in Q2, now owning 439,341 shares worth $6.5 million. Other investors also adjusted their stakes. Travere's stock opened at $35.19, with a market cap of $3.15 billion. The company reported Q3 earnings of $0.28 per share, beating estimates, with revenue up 162.1% year-over-year. Insiders sold shares worth $7.22 million recently. Analysts have mixed ratings, with price targets ranging from $25 to $48.

Loomis Sayles & Co. L P Trims Position in Travere Therapeutics, Inc. $TVTX